Item 7.01 Regulation FD.
OnMarch 14, 2022 ,AnaptysBio, Inc. issued a press release announcing imsidolimab ACORN Phase 2 clinical trial data in moderate-to-severe acne. A copy of the press release is attached as Exhibit 99.1 to this report and incorporated herein by reference. The information within this report, including Exhibit 99.1 to this Current Report on Form 8-K, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this report and in the accompanying Exhibit 99.1 shall not be incorporated by reference into any registration statement or other document filed byAnaptysBio with theSecurities and Exchange Commission , whether made before or after the date of this Current Report on Form 8-K, regardless of any general incorporation language in such filing (or any reference to this Current Report on Form 8-K generally), except as shall be expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits
Exhibit Number Exhibit Title or Description 99.1 Press release issued byAnaptysBio, Inc.
regarding imsidolimab ACORN Phase
2 clinical trial data in moderate-to-severe acne, datedMarch 14, 2022 . 104 Cover Page Interactive Data File (the cover
page XBRL tags are embedded
within the inline XBRL document).
--------------------------------------------------------------------------------
© Edgar Online, source